Monopar Therapeutics Inc (1IY0) Price & Analysis

0 Followers

1IY0 Stock Chart & Stats

€93.20

-€4.40(-4.61%)

At close: Jul 24 4:00 PM EDT

€93.20

-€4.40(-4.61%)

Day’s Range― - ―

52-Week Range€27.00 - €103.40

Previous CloseN/A

Volume0.00

Average Volume (3M)3.00

Market Cap

€655.19M

Enterprise Value€656.75

Total Cash (Recent Filing)€134.30M

Total Debt (Recent Filing)€107.83K

Price to Earnings (P/E)―

Beta9.35

Next Earnings

Nov 06, 2026

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.34

Shares Outstanding6,712,172

10 Day Avg. Volume0

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio-0.98

Price to Book (P/B)3.51

Price to Sales (P/S)0.00

P/FCF Ratio-39.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€103.85

Price Target Upside11.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-2.51

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress For ALXN1840The rolling NDA and multiple FDA designations advance ALXN1840 toward potential U.S. approval while providing regulatory incentives. This strengthens the company’s development position in Wilson disease, although approval is not assured.

Positive Clinical Efficacy And SafetyReplicated efficacy and favorable safety across substantial patient exposure support ALXN1840’s clinical differentiation. These results may improve the probability of regulatory success and create a stronger foundation for future commercialization.

Low Leverage And Substantial Capital BaseNear-zero leverage limits debt-related financial risk and preserves flexibility while the company funds clinical and regulatory work. The sizable equity and asset base provides a stronger buffer than a highly indebted development-stage biotech.

Bears Say

No Product RevenueWithout recurring product revenue, Monopar has no demonstrated operating base to fund research, regulatory filings or commercialization. Its financial outlook remains dependent on successful approval and launch of a candidate or other external funding.

Widening Net LossesLosses are rising while revenue remains absent, indicating that development spending has not yet produced commercialization progress in the reported financials. Continued losses could erode equity and increase the capital required to reach approval.

Persistent Cash Burn And Funding DependenceThe company has not demonstrated internally funded operations or a sustained path to breakeven cash flow. Even excluding the reported TTM anomaly, ongoing burn implies reliance on equity or other external capital to continue development.

Monopar Therapeutics Inc News

Monopar Therapeutics price target raised to $130 from $115 at Morgan Stanley

Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Monopar Therapeutics (MNPR) to $130 from $115...

11d ago

MNPR

Monopar Therapeutics reports Q2 EPS (62c), consensus (65c)

On July 22, Monopar announced it had initiated the rolling submission of a New Drug Application to the...

11d ago

MNPR

Monopar Therapeutics sees cash runway through December 31, 2027

Cash, cash equivalents and investments as of June 30, were $134.3M. Monopar expects its current funds to support...

11d ago

MNPR

Monopar Therapeutics price target raised to $133 from $117 at BTIG

BTIG analyst Jeet Mukherjee raised the firm’s price target on Monopar Therapeutics (MNPR) to $133 from $117 and...

11d ago

MNPR

Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics (MNPR) to Neutral from Overweight with a price target of...

11d ago

MNPR

Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics (MNPR) to Neutral from Overweight with a price target of...

11d ago

MNPR

Monopar Therapeutics price target raised to $128 from $125 at Barclays

Barclays raised the firm’s price target on Monopar Therapeutics (MNPR) to $128 from $125 and keeps an Overweight...

11d ago

MNPR

Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

11d ago

ALC

Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Monopar Therapeutics Inc, retaining the price...

15d ago

MNPR

Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile

JonesTrading analyst Boris Peaker maintained a Buy rating on Monopar Therapeutics Inc today and set a price target...

16d ago

MNPR

BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup

Analyst Jeet Mukherjee of BTIG maintained a Buy rating on Monopar Therapeutics Inc, with a price target of...

1M ago

MNPR

Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Monopar Therapeutics...

1M ago

MNPR

Monopar price target raised to $125 from $105 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $125 from $105 and keeps a...

1M ago

MNPR

Monopar Begins Rolling FDA NDA Submission for ALXN1840

An announcement from Monopar Therapeutics Inc ( ($MNPR) ) is now available. On July 22, 2026, Monopar Therapeutics...

1M ago

MNPR

1IY0 FAQ

What was Monopar Therapeutics Inc’s price range in the past 12 months?

Monopar Therapeutics Inc lowest stock price was €27.00 and its highest was €103.40 in the past 12 months.

What is Monopar Therapeutics Inc’s market cap?

Monopar Therapeutics Inc’s market cap is €655.19M.

When is Monopar Therapeutics Inc’s upcoming earnings report date?

Monopar Therapeutics Inc’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.

How were Monopar Therapeutics Inc’s earnings last quarter?

Monopar Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -€0.532 earnings per share for the quarter, beating the consensus estimate of -€0.552 by €0.02.

Is Monopar Therapeutics Inc overvalued?

According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monopar Therapeutics Inc pay dividends?

Monopar Therapeutics Inc does not currently pay dividends.

What is Monopar Therapeutics Inc’s EPS estimate?

Monopar Therapeutics Inc’s EPS estimate is -0.69.

How many shares outstanding does Monopar Therapeutics Inc have?

Monopar Therapeutics Inc has 6,712,172 shares outstanding.

What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?

Monopar Therapeutics Inc reported an EPS of -€0.532 in its last earnings report, beating expectations of -€0.552. Following the earnings report the stock price went down -1.521%.

Which hedge fund is a major shareholder of Monopar Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:1IY0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Monopar Therapeutics Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

150.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Inc (1IY0) Earnings & Revenues

Historic Earnings Reports

1IY0 Stock 12 Month Forecast

Average Price Target

€103.85

▲(11.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"€27","49":"€49","71":"€71","93":"€93","115":"€115"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":114.03026719,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€114.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.84899333375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€103.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.59441343,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€86.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,49,71,93,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,99.14078978384616,100.38157956769231,101.62236935153847,102.86315913538462,104.10394891923077,105.34473870307693,106.58552848692308,107.82631827076924,109.06710805461539,110.30789783846154,111.5486876223077,112.78947740615385,{"y":114.03026719,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,98.35761487182693,98.81522974365384,99.27284461548078,99.7304594873077,100.18807435913462,100.64568923096154,101.10330410278847,101.56091897461539,102.01853384644231,102.47614871826923,102.93376359009616,103.39137846192308,{"y":103.84899333375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,97.03033949461539,96.16067898923077,95.29101848384616,94.42135797846154,93.55169747307693,92.68203696769231,91.8123764623077,90.94271595692308,90.07305545153847,89.20339494615385,88.33373444076923,87.46407393538462,{"y":86.59441343,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >